Transfemoral Valve-in-Valve TAVI with MyVal for Failed Surgical Aortic Bioprostheses: Procedural Outcomes, Serial Hemodynamics, and Anatomy-Based Determinants of Residual Gradient
Journal of Clinical Medicine · 01.05.2026 · 15 (9) · 3462
DOI: 10.3390/jcm15093462 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 01.05.2026. Verfasst von Georgios E Papadopoulos und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Department, Interbalkan Medical Center, 57001 Thessaloniki, Greece. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) is an established treatment for failed surgical aortic bioprostheses, but dedicated data on the MyVal platform remain limited. We evaluated outcomes, hemodynamics, residual gradient, and an exploratory matched comparison with ACURATE neo2.
Methods
This prospective, single-center cohort included consecutive patients with failed surgical aortic bioprostheses treated with MyVal ViV-TAVI between July 2022 and June 2025. Outcomes were reported according to VARC-3.
Results
Sixty-eight patients were included (age 77 ± 7 years; 51.5% women; EuroSCORE II 7.3 ± 1.8%). Technical success was 100%, with no 30-day death, stroke, myocardial infarction, second-valve implantation, or emergency surgical conversion. Mean gradient decreased from 38.0 ± 9.5 mmHg at baseline to 6.7 ± 2.1 mmHg post-procedure and remained low at 1 year (8.1 ± 2.5 mmHg; overall p < 0.001). AVA increased from 0.80 ± 0.23 cm2 to 1.98 ± 0.19 cm2 post-procedure and was 1.86 ± 0.23 cm2 at 1 year (overall p < 0.001). Smaller true internal diameter independently predicted elevated 1-year gradient (adjusted OR per 1-mm decrease 1.33, 95% CI 1.04–1.78; p = 0.028). In the exploratory matched comparison, safety and hemodynamic outcomes did not differ significantly between MyVal and ACURATE neo2. At a median follow-up of 12.8 months, all-cause mortality and heart failure hospitalization were each 4.4%.
Conclusions
In this prospective single-center cohort, MyVal ViV-TAVI was associated with high procedural success and favorable 1-year hemodynamic outcomes, with residual gradient driven mainly by small surgical valve true internal diameter.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cardiology Department, Interbalkan Medical Center, 57001 Thessaloniki, Greece.
ORCID-Profile: Georgios E Papadopoulos, Ilias Ninios, Sotirios Evangelou, Vlasis Ninios
Zitieren
APA
Papadopoulos, G. E., Ninios, I., Evangelou, S., Ioannides, A., Nikitopoulos, A., & Ninios, V. (2026). Transfemoral Valve-in-Valve TAVI with MyVal for Failed Surgical Aortic Bioprostheses: Procedural Outcomes, Serial Hemodynamics, and Anatomy-Based Determinants of Residual Gradient. Journal of Clinical Medicine, 15(9), 3462. https://doi.org/10.3390/jcm15093462
Vancouver
Papadopoulos GE, Ninios I, Evangelou S, Ioannides A, Nikitopoulos A, Ninios V. Transfemoral Valve-in-Valve TAVI with MyVal for Failed Surgical Aortic Bioprostheses: Procedural Outcomes, Serial Hemodynamics, and Anatomy-Based Determinants of Residual Gradient. Journal of Clinical Medicine. 2026;15(9):3462. doi:10.3390/jcm15093462
BibTeX
@article{Papadopoulos2026,
author = {Papadopoulos, Georgios E and Ninios, Ilias and Evangelou, Sotirios and Ioannides, Andreas and Nikitopoulos, Athinodoros and Ninios, Vlasis},
title = {Transfemoral Valve-in-Valve TAVI with MyVal for Failed Surgical Aortic Bioprostheses: Procedural Outcomes, Serial Hemodynamics, and Anatomy-Based Determinants of Residual Gradient},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {9},
pages = {3462},
doi = {10.3390/jcm15093462}
}
EUVIMED